scholarly journals The Challenge for the Dental Community-Bisphosphonate-Related Osteonecrosis of the Jaw

2016 ◽  
Vol 01 (04) ◽  
Author(s):  
Angel Bakardjiev
Keyword(s):  
Osteonecrosis Of The Jaw

Hypercalcaemia and osteonecrosis of the jaw in association with denosumab use in the paediatric population

2019 ◽  
Author(s):  
Christie-Lee Wall ◽  
Verity Pacey ◽  
Kelly Gray ◽  
Richard McGee ◽  
Melissa Fiscaletti ◽  
...  
Keyword(s):  
Paediatric Population ◽  
Osteonecrosis Of The Jaw

The incidence of Bisphosphonate related Osteonecrosis of the Jaw (BONJ) in patients treated with oral bisphosphonates for osteoporosis

2017 ◽  
Author(s):  
Fergus MacLean ◽  
Rebecca Mason ◽  
Jeff Downie ◽  
Iain Watt ◽  
Andrew Gallagher ◽  
...  
Keyword(s):  
Osteonecrosis Of The Jaw ◽  
Oral Bisphosphonates

scholarly journals Porphyromonas, Treponema, and Mogibacterium promote IL8/IFNγ/TNFα-based pro-inflammation in patients with medication-related osteonecrosis of the jaw

2020 ◽  
Vol 13 (1) ◽  
pp. 1851112
Author(s):  
Qingxiang Li ◽  
Yinfei Pu ◽  
Han Lu ◽  
Ning Zhao ◽  
Yifei Wang ◽  
...  
Keyword(s):  
Osteonecrosis Of The Jaw

scholarly journals Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates

2021 ◽  
Author(s):  
L. Lorusso ◽  
L. Pieruzzi ◽  
M. Gabriele ◽  
M. Nisi ◽  
D. Viola ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Side Effect ◽  
Kinase Inhibitors ◽  
Osteonecrosis Of The Jaw ◽  
Antiangiogenic Agents ◽  
Neoplastic Disease ◽  
External Radiation Therapy ◽  
Serious Disease

AbstractOsteonecrosis of the jaw (ONJ) is a rare but very serious disease that can affect both jaws. It is defined as exposed bone in the maxillofacial region that does not heal within 8 weeks after a health care provider identification. ONJ can occur spontaneously or can be due to drugs like bisphosphonates (BPS) and anti-RANK agents, in patients with no history of external radiation therapy in the craniofacial region. Although in phase 3 trials of tyrosine kinase inhibitors (TKIs) used in thyroid cancer (TC) the ONJ was not reported among the most common side effects, several papers reported the association between ONJ and TKIs, both when they are used alone and in combination with a bisphosphonate. The appearance of an ONJ in a patient with metastatic radio-iodine refractory differentiated TC, treated with zoledronic acid and sorafenib, has put us in front of an important clinical challenge: when a ONJ occurred during TKIs treatment, it really worsens the patients’ quality of life. We should consider that in the case of ONJ a TKI discontinuation becomes necessary, and this could lead to a progression of neoplastic disease. The most important aim of this review is to aware the endocrinologists/oncologists dealing with TC to pay attention to this possible side effect of BPS and TKIs, especially when they are used in association. To significantly reduced the risk of ONJ, both preventive measures before initiating not only antiresorptive therapy but also antiangiogenic agents, and regular dental examinations during the treatment should always be proposed.

Sign in / Sign up

Export Citation Format

Share Document